Bio-innovation is increasingly recognized as a critical driver of economic resilience, industrial competitiveness, sustainability, and healthier societies. Advances in DNA-related technologies are reshaping industries ranging from food and agriculture to materials, chemicals, energy, and health. Yet despite growing momentum, adoption remains constrained by high costs, scaling challenges, fragmented data, and limited policy readiness.
The Bioeconomy Initiative brings together leaders across government, industry, academia, and civil society to accelerate the adoption of bio-innovation and help build resilient, sustainable, and competitive economic systems.
The Bioeconomy Initiative accelerates the global transition to a technology-driven bioeconomy by convening leaders across government, industry, academia, and civil society to advance bio-innovation that strengthens economic resilience, industrial competitiveness, sustainability, and societal well-being.

Translate scientific and technical complexity into clear, accessible narratives that help stakeholders understand the economic, environmental and societal value of bio-innovation.

Advance more resilient, future-ready value chains by helping scale bio-innovation across sectors such as food systems, materials, chemicals, health and energy.

Support policy and regulatory approaches that enable responsible bio-innovation through cross-sector collaboration, practical guidance and regulatory sandboxes that help accelerate adoption.
This report presents insights into how governments can move from bioeconomy strategy to implementation, and identifies policy actions to unlock private investment, scale domestic manufacturing and build future-ready workforces.
This paper presents insights into how bio-innovation can move beyond technology-led development to deliver differentiated commercial value, and identifies opportunities for businesses, investors and policy-makers to unlock scalable bioeconomy transformation.
This report presents insights into how technology-enabled bio-innovation can accelerate the transition to a commercial bioeconomy, and identifies opportunities for policy, business and research leaders to turn biological engineering into scalable market impact.

China is the second-largest developer of new medicines, with its companies running an increasing share of the world’s clinical trials. It is also rising to the top in several critical areas of research, including cancer. As discovery accelerates, what will faster and more competitive drug development mean for patients and how will it affect the prices they pay?


Bioeconomy Initiative
A World Economic Forum Initiative